donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NVO Novo-Nordisk A/S > Company Profile
NVO Novo-Nordisk A/S
111.640
+0.210+0.19%
Post Mkt Price
111.64000.00%
Symbol
NVO
Company Name
Novo Nordisk A/S
Listing Date
07/09/1981
Establishment Date
1923
CEO
Jorgensen, Lars Fruergaard
Market
NYSE
Employees
49,295
Securities Type
DR
ADS Ratio
1.0 : 1.0
Fiscal Year Ends
December 31
Address
Novo Allé 1
City
Bagsv?rd
Province
Capital Region
Country
Denmark
Zip code
2880
Phone
45-44-44-88-88
Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Company Overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
CEO: Jorgensen, Lars Fruergaard
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...